[{"id":"2e87885c-4e7c-4eee-af7f-c60a1af4ea15","acronym":"SPIRAL","url":"https://clinicaltrials.gov/study/NCT06785974","created_at":"2025-02-25T19:12:33.814Z","updated_at":"2025-02-25T19:12:33.814Z","phase":"Phase 4","brief_title":"Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis","source_id_and_acronym":"NCT06785974 - SPIRAL","lead_sponsor":"Erasmus Medical Center","biomarkers":" IL6 • TNFA • IL10 • IL1B • CRP","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL10 • IL1B • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atorvastatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 02/01/2025","start_date":" 02/01/2025","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2030","study_completion_date":" 02/01/2030","last_update_posted":"2025-01-22"},{"id":"ef502e78-36b6-4881-b791-586dbda2fa9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04379999","created_at":"2021-01-18T21:09:15.617Z","updated_at":"2024-07-02T16:34:26.352Z","phase":"Phase 1","brief_title":"Atorvastatin ± Aspirin in Lynch Syndrome Syndrome","source_id_and_acronym":"NCT04379999","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" MLH1 • MSH6 • MSH2 • EPCAM • CASP3","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["MLH1 • MSH6 • MSH2 • EPCAM • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation • PMS2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atorvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 09/10/2018","start_date":" 09/10/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-13"},{"id":"0cfe572f-7934-4703-b8bb-bebef2998a06","acronym":"","url":"https://clinicaltrials.gov/study/NCT04862260","created_at":"2021-04-27T14:52:42.546Z","updated_at":"2024-07-02T16:35:01.875Z","phase":"Phase 1","brief_title":"Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT04862260","lead_sponsor":"CHU de Quebec-Universite Laval","biomarkers":" APOA1 • APOC3 • ANGPTL3 • ANGPTL8","pipe":"","alterations":" ","tags":["APOA1 • APOC3 • ANGPTL3 • ANGPTL8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Repatha (evolocumab) • atorvastatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3","initiation":"Initiation: 10/04/2021","start_date":" 10/04/2021","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-22"},{"id":"eb1b4b01-c1ee-4614-a635-a45ea2b016b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03872388","created_at":"2021-01-18T19:05:38.473Z","updated_at":"2024-07-02T16:35:09.552Z","phase":"Phase 2","brief_title":"Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy","source_id_and_acronym":"NCT03872388","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • atorvastatin"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 01/14/2019","start_date":" 01/14/2019","primary_txt":" Primary completion: 10/19/2023","primary_completion_date":" 10/19/2023","study_txt":" Completion: 10/19/2023","study_completion_date":" 10/19/2023","last_update_posted":"2024-04-16"},{"id":"e61b2a2a-8b63-44e3-9ab5-9ad51bd15dc7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03560882","created_at":"2021-01-18T17:31:32.363Z","updated_at":"2024-07-02T16:35:13.417Z","phase":"Phase 1","brief_title":"A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies","source_id_and_acronym":"NCT03560882","lead_sponsor":"Joaquina Baranda","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atorvastatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/19/2018","start_date":" 07/19/2018","primary_txt":" Primary completion: 10/14/2022","primary_completion_date":" 10/14/2022","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-03-21"},{"id":"3104beed-64b4-4837-ba0b-5ffd15be0444","acronym":"","url":"https://clinicaltrials.gov/study/NCT04767984","created_at":"2021-02-24T14:55:38.313Z","updated_at":"2024-07-02T16:35:22.455Z","phase":"Phase 2","brief_title":"Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis","source_id_and_acronym":"NCT04767984","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atorvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 09/24/2021","start_date":" 09/24/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-01-24"},{"id":"5e4173a0-f1b6-45fa-9023-3e3fc9e7ede2","acronym":"YAPPETIZER","url":"https://clinicaltrials.gov/study/NCT03358017","created_at":"2021-01-18T16:34:31.703Z","updated_at":"2024-07-02T16:35:32.529Z","phase":"Phase 2","brief_title":"Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer","source_id_and_acronym":"NCT03358017 - YAPPETIZER","lead_sponsor":"Mario Negri Institute for Pharmacological Research","biomarkers":" HER-2 • TP53 • PGR • BRCA • TAFAZZIN","pipe":" | ","alterations":" PGR negative","tags":["HER-2 • TP53 • PGR • BRCA • TAFAZZIN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zoledronic acid • atorvastatin"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 03/05/2018","start_date":" 03/05/2018","primary_txt":" Primary completion: 06/17/2021","primary_completion_date":" 06/17/2021","study_txt":" Completion: 07/25/2023","study_completion_date":" 07/25/2023","last_update_posted":"2023-10-19"},{"id":"0832f425-1674-469e-b2f7-05cb2959cee1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05103644","created_at":"2021-11-02T17:57:09.080Z","updated_at":"2024-07-02T16:36:01.226Z","phase":"Phase 2/3","brief_title":"Study of the Therapeutic Effect of Atorvastatin on the Clinical Outcomes in HER2 Negative Breast Cancer Patients\"","source_id_and_acronym":"NCT05103644","lead_sponsor":"Beni-Suef University","biomarkers":" HER-2 • WWTR1 • TAFAZZIN","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • WWTR1 • TAFAZZIN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atorvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/30/2021","start_date":" 10/30/2021","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2022-11-02"},{"id":"767668bb-7660-4716-a504-9448522511e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04601116","created_at":"2021-01-19T20:30:28.646Z","updated_at":"2024-07-02T16:36:36.015Z","phase":"Phase 3","brief_title":"The MASTER Study (MAmmary Cancer STatin ER Positive Study)","source_id_and_acronym":"NCT04601116","lead_sponsor":"Aarhus University Hospital","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atorvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 3360","initiation":"Initiation: 01/04/2021","start_date":" 01/04/2021","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2035","study_completion_date":" 01/01/2035","last_update_posted":"2021-01-14"},{"id":"cfadf814-6011-48cb-93a2-6f8f551b1508","acronym":"ABC-SE","url":"https://clinicaltrials.gov/study/NCT02958852","created_at":"2021-01-18T14:32:07.915Z","updated_at":"2024-07-02T16:36:41.455Z","phase":"Phase 2","brief_title":"A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT02958852 - ABC-SE","lead_sponsor":"Lund University Hospital","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • letrozole • atorvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2020-09-02"},{"id":"9c655582-8e2f-460a-9a14-8195852475ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT04151355","created_at":"2021-01-18T20:15:56.016Z","updated_at":"2024-07-02T16:36:53.943Z","phase":"","brief_title":"Effect of Atorvastatin on 5-Fluorouracil Induced Mucositis","source_id_and_acronym":"NCT04151355","lead_sponsor":"Ain Shams University","biomarkers":" TNFA","pipe":"","alterations":" ","tags":["TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • irinotecan • atorvastatin"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 10/01/2019","start_date":" 10/01/2019","primary_txt":" Primary completion: 09/30/2020","primary_completion_date":" 09/30/2020","study_txt":" Completion: 09/30/2020","study_completion_date":" 09/30/2020","last_update_posted":"2019-11-05"},{"id":"ff4b5713-5db4-4421-b52f-92fd220f2472","acronym":"","url":"https://clinicaltrials.gov/study/NCT01491958","created_at":"2021-01-18T06:14:38.288Z","updated_at":"2024-07-02T16:37:14.624Z","phase":"Phase 2","brief_title":"Safety \u0026 Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation","source_id_and_acronym":"NCT01491958","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atorvastatin"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 12/10/2011","start_date":" 12/10/2011","primary_txt":" Primary completion: 01/01/2014","primary_completion_date":" 01/01/2014","study_txt":" Completion: 06/27/2016","study_completion_date":" 06/27/2016","last_update_posted":"2018-01-23"},{"id":"8f0d03c5-23ac-4cf6-8679-f7ad9080d8a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00335504","created_at":"2021-01-18T01:09:30.358Z","updated_at":"2024-07-02T16:37:25.648Z","phase":"Phase 2","brief_title":"Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia","source_id_and_acronym":"NCT00335504","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CASP3","pipe":"","alterations":" ","tags":["CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atorvastatin"],"overall_status":"Completed","enrollment":" Enrollment 85","initiation":"Initiation: 03/01/2006","start_date":" 03/01/2006","primary_txt":" Primary completion: 04/01/2009","primary_completion_date":" 04/01/2009","study_txt":" Completion: 04/01/2009","study_completion_date":" 04/01/2009","last_update_posted":"2017-02-15"},{"id":"a6da7bef-70ac-4c06-ad81-639e48871bba","acronym":"","url":"https://clinicaltrials.gov/study/NCT00637481","created_at":"2021-01-18T02:22:22.416Z","updated_at":"2024-07-02T16:37:26.842Z","phase":"Phase 1","brief_title":"A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer","source_id_and_acronym":"NCT00637481","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atorvastatin"],"overall_status":"Completed","enrollment":" Enrollment 66","initiation":"Initiation: 03/01/2008","start_date":" 03/01/2008","primary_txt":" Primary completion: 10/01/2012","primary_completion_date":" 10/01/2012","study_txt":" Completion: 10/01/2012","study_completion_date":" 10/01/2012","last_update_posted":"2016-12-29"}]